Login to Your Account



Biolinerx Teams with Jiangsu for Hepatitis C Drug in China

By Shannon Ellis
Contributing Writer

Wednesday, June 19, 2013

SHANGHAI, China – A licensing agreement may help troubled Israeli firm Biolinerx Ltd. get a toehold in China with its hepatitis C virus (HCV) treatment BL-8030.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription